New drug cocktail aims to outsmart resistant leukemia
NCT ID NCT06232655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs, cladribine and venetoclax, in 20 adults with a specific form of acute myeloid leukemia (monocytic AML) that has stopped responding to or returned after standard treatment. The goal is to see if this new combo can shrink or eliminate the cancer. Researchers will also monitor side effects and how long any benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cladribine and venetoclax (chemotherapy and targeted therapy drugs)
What this could lead to
If successful, this could offer a new treatment option for people with a hard-to-treat form of acute myeloid leukemia that has stopped responding to standard therapy.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. The drugs can cause serious side effects, and there is no guarantee the combination will work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universtiy of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact